SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ron H. J. Mathijssen, Alex Sparreboom, Jaap Verweij, Determining the optimal dose in the development of anticancer agents, Nature Reviews Clinical Oncology, 2014, 11, 5, 272

    CrossRef

  2. 2
    Roelof W F van Leeuwen, Teun van Gelder, Ron H J Mathijssen, Frank G A Jansman, Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective, The Lancet Oncology, 2014, 15, 8, e315

    CrossRef

  3. 3
    Jie Shao, John S. Markowitz, Di Bei, Guohua An, Enzyme- and Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors, Journal of Pharmaceutical Sciences, 2014, 103, 12
  4. 4
    W. Weitschies, Orale Bioverfügbarkeit onkologischer Präparate, Der Urologe, 2014, 53, 12, 1772

    CrossRef

  5. 5
    Marc R. Yago, Adam Frymoyer, Leslie Z. Benet, Gillian S. Smelick, Lynda A. Frassetto, Xiao Ding, Brian Dean, Laurent Salphati, Nageshwar Budha, Jin Y. Jin, Mark J. Dresser, Joseph A. Ware, The Use of Betaine HCl to Enhance Dasatinib Absorption in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria, The AAPS Journal, 2014, 16, 6, 1358

    CrossRef

  6. 6
    Hesham M. Korashy, A.F.M. Motiur Rahman, Mohammed Gabr Kassem, 2014,

    CrossRef

  7. 7
    Debra H. Josephs, Danielle S. Fisher, James Spicer, Robert J. Flanagan, Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors, Therapeutic Drug Monitoring, 2013, 1

    CrossRef

  8. 8
    Ophelia Q. P. Yin, Véronique Bédoucha, Tracey McCulloch, Cheng Zheng, Wei Zhou, Azra Hussaini, Steven Novick, Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers, Cancer Chemotherapy and Pharmacology, 2013, 71, 1, 219

    CrossRef

  9. 9
    Marc R. Yago, Adam R. Frymoyer, Gillian S. Smelick, Lynda A. Frassetto, Nageshwar R. Budha, Mark J. Dresser, Joseph A. Ware, Leslie Z. Benet, Gastric Reacidification with Betaine HCl in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria, Molecular Pharmaceutics, 2013, 10, 11, 4032

    CrossRef

  10. 10
    Esther Carcelero, Helena Anglada, Montse Tuset, Natalia Creus, Interactions between oral antineoplastic agents and concomitant medication: a systematic review, Expert Opinion on Drug Safety, 2013, 12, 3, 403

    CrossRef

  11. 11
    Joseph W. Lubach, Jacob Z. Chen, Jonathan Hau, Jose Imperio, Melis Coraggio, Lichuan Liu, Harvey Wong, Investigation of the Rat Model for Preclinical Evaluation of pH-Dependent Oral Absorption in Humans, Molecular Pharmaceutics, 2013, 10, 11, 3997

    CrossRef

  12. 12
    Frederik E. Stuurman, Bastiaan Nuijen, Jos H. Beijnen, Jan H. M. Schellens, Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement, Clinical Pharmacokinetics, 2013, 52, 6, 399

    CrossRef

  13. 13
    Jodie Pang, Gena Dalziel, Brian Dean, Joseph A. Ware, Laurent Salphati, Pharmacokinetics and Absorption of the Anticancer Agents Dasatinib and GDC-0941 under Various Gastric Conditions in Dogs – Reversing the Effect of Elevated Gastric pH with Betaine HCl, Molecular Pharmaceutics, 2013, 10, 11, 4024

    CrossRef

  14. 14
    Gillian S. Smelick, Timothy P. Heffron, Laura Chu, Brian Dean, David A. West, Scott L. DuVall, Bert L. Lum, Nageshwar Budha, Scott N. Holden, Leslie Z. Benet, Adam Frymoyer, Mark J. Dresser, Joseph A. Ware, Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development, Molecular Pharmaceutics, 2013, 10, 11, 4055

    CrossRef

  15. 15
    Ophelia Q. P. Yin, Frank J. Giles, Michele Baccarani, Philipp le Coutre, Ovidiu Chiparus, Neil Gallagher, Giuseppe Saglio, Timothy P. Hughes, Andreas Hochhaus, Hagop M. Kantarjian, Richard A. Larson, Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia, Cancer Chemotherapy and Pharmacology, 2012, 70, 2, 345

    CrossRef

  16. 16
    Fabio P S Santos, Jorge Cortes, Dasatinib for the treatment of Philadelphia chromosome-positive leukemias, Expert Opinion on Pharmacotherapy, 2012, 13, 16, 2381

    CrossRef

  17. 17
    N R Budha, A Frymoyer, G S Smelick, J Y Jin, M R Yago, M J Dresser, S N Holden, L Z Benet, J A Ware, Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?, Clinical Pharmacology & Therapeutics, 2012, 92, 2
  18. 18
    David A. Reardon, James J. Vredenburgh, Annick Desjardins, Katherine B. Peters, Sith Sathornsumetee, Stevie Threatt, John H. Sampson, James E. Herndon, April Coan, Frances McSherry, Jeremy N. Rich, Roger E. McLendon, Steven Zhang, Henry S. Friedman, Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma, Journal of Neuro-Oncology, 2012, 108, 3, 499

    CrossRef

  19. 19
    Paola Di Gion, Friederike Kanefendt, Andreas Lindauer, Matthias Scheffler, Oxana Doroshyenko, Uwe Fuhr, Jürgen Wolf , Ulrich Jaehde, Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors, Clinical Pharmacokinetics, 2011, 50, 9, 551

    CrossRef

  20. 20
    Ryuichi Ogawa, Hirotoshi Echizen, Clinically Significant Drug Interactions with Antacids, Drugs, 2011, 71, 14, 1839

    CrossRef

  21. 21
    Paul L. McCormack, Susan J. Keam, Dasatinib, Drugs, 2011, 71, 13, 1771

    CrossRef

  22. 22
    Amber Fullmer, Hagop Kantarjian, Jorge Cortes, Elias Jabbour, Dasatinib for the treatment of chronic myeloid leukemia, Expert Review of Hematology, 2011, 4, 3, 253

    CrossRef

  23. 23
    A. Haouala, N. Widmer, M. A. Duchosal, M. Montemurro, T. Buclin, L. A. Decosterd, Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib, Blood, 2011, 117, 8, e75

    CrossRef

  24. 24
    M H Hanigan, B L Cruz, S S Shord, P J Medina, J Fazili, D M Thompson, Optimizing Chemotherapy: Concomitant Medication Lists, Clinical Pharmacology & Therapeutics, 2011, 89, 1
  25. 25
    Kamakshi V. Rao, Andrea Iannucci, Elias Jabbour, Current and Future Clinical Strategies in the Management of Chronic Myeloid Leukemia, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010, 30, 9P2
  26. 26
    Ophelia Q. P. Yin, Neil Gallagher, Deirdre Fischer, Eren Demirhan, Wei Zhou, Georg Golor, Horst Schran, Effect of the Proton Pump Inhibitor Esomeprazole on the Oral Absorption and Pharmacokinetics of Nilotinib, The Journal of Clinical Pharmacology, 2010, 50, 8
  27. 27
    Shin Ogita, Patricia LoRusso, Jing Li, Oral Chemotherapeutic Agents, Encyclopedia of Drug Metabolism and Interactions,